Weekly Sepsis Research Analysis
This week’s sepsis literature emphasized rapid bedside phenotyping and biomarker-guided triage, host-directed anti‑virulence strategies, and mechanistic discoveries that nominate new therapeutic axes. A large pragmatic RCT showed procalcitonin-guided ED assessment reduced 28‑day mortality; prospective near‑patient ARDS subphenotyping operationalized precision critical care at the bedside; and a mechanistic host‑pathogen study identified a STAT1-dependent axis that can be repurposed to mitigate M
Summary
This week’s sepsis literature emphasized rapid bedside phenotyping and biomarker-guided triage, host-directed anti‑virulence strategies, and mechanistic discoveries that nominate new therapeutic axes. A large pragmatic RCT showed procalcitonin-guided ED assessment reduced 28‑day mortality; prospective near‑patient ARDS subphenotyping operationalized precision critical care at the bedside; and a mechanistic host‑pathogen study identified a STAT1-dependent axis that can be repurposed to mitigate MRSA sepsis in mice. Cross-cutting themes include diagnostics and rapid phenotyping, trajectory-aware ML and implementation, antimicrobial stewardship in resistant infections, and multiple preclinical molecular targets ready for translational work.
Selected Articles
1. Targeting phenol-soluble modulin α3-driven M1 macrophage polarization and necroptosis mitigates MRSA infection in mice.
Mechanistic preclinical work shows MRSA virulence factor PSMα3 drives M1 macrophage polarization and necroptosis through an ISGF3–necrosome axis downstream of FPR2. Pharmacologic inhibition of STAT1 with the approved drug fludarabine reduced MRSA burden and improved outcomes in murine sepsis and pneumonia models, supporting host‑directed anti‑virulence strategies.
Impact: Identifies a targetable, host‑pathogen signaling axis and demonstrates efficacy with a repurposed clinically available drug in sepsis-relevant models, accelerating translational prospects.
Clinical Implications: Supports development of adjunctive, anti‑virulence therapies for MRSA sepsis; next steps should define safety, dosing, and patient selection biomarkers (e.g., PSMα3 activity) before human trials.
Key Findings
- PSMα3 promotes M1 macrophage polarization and necroptosis via an ISGF3–necrosome interaction.
- FPR2 functions as the receptor mediating PSMα3 effects.
- STAT1 inhibition with fludarabine mitigated MRSA infection in murine sepsis and pneumonia models.
2. Procalcitonin testing combined with NEWS2 evaluation compared with usual care based on NEWS2 for identification of sepsis and antibiotic initiation in the emergency department in England and Wales (PRONTO): a multicentre, randomised, controlled, open-label, phase 3 trial.
A large pragmatic multicentre RCT (n=7,667) found that adding rapid procalcitonin testing to NEWS2 did not change 3‑hour IV antibiotic initiation but reduced 28‑day mortality (13.6% vs 16.6%). The procalcitonin result influenced clinician decisions in ~65% of cases, indicating potential mortality benefit from biomarker‑guided triage independent of immediate antibiotic timing.
Impact: A high‑quality phase 3 pragmatic RCT demonstrating mortality reduction with biomarker-guided ED assessment provides powerful evidence to change triage workflows and informs stewardship and implementation strategies.
Clinical Implications: Implement near‑patient procalcitonin testing alongside NEWS2 in ED workflows warrants consideration, with attention to implementation science, clinician adherence, and evaluation of stewardship impacts (duration of antibiotics, de‑escalation).
Key Findings
- No difference in IV antibiotic initiation at 3 hours (48.4% vs 48.2%).
- Lower 28‑day mortality with procalcitonin‑guided care (13.6% vs 16.6%; adjusted risk difference −3.12%).
- Procalcitonin influenced clinical decision‑making in ~64.7% of cases; adverse events similar between groups.
3. Bedside identification of subphenotypes in acute respiratory failure (PHIND): a multicentre, observational cohort study.
The PHIND prospective multicentre cohort (n=512) used a 1‑hour near‑patient assay (IL‑6, soluble TNFR1) plus bicarbonate to classify ARDS/AHRF into hyper‑ vs hypoinflammatory subphenotypes; hyperinflammatory patients had markedly higher 60‑day mortality (51% vs 28%). The study operationalizes rapid bedside subphenotyping suitable for precision enrolment and targeted interventions.
Impact: First prospective demonstration that an actionable, 1‑hour bedside assay can reproducibly stratify ARDS subphenotypes with large prognostic separation, enabling precision trial design and stage‑specific therapy.
Clinical Implications: ICUs and ED/wards managing acute respiratory failure can feasibly implement near‑patient IL‑6/sTNFR1 + bicarbonate testing to stratify patients for targeted therapies and trial enrollment; operational pathways and reagent/platform access are immediate implementation considerations.
Key Findings
- Near‑patient IL‑6, sTNFR1 and bicarbonate classified ~18% as hyperinflammatory and 82% as hypoinflammatory within ~1 hour.
- 60‑day mortality was 51% in hyperinflammatory vs 28% in hypoinflammatory ARDS (adjusted OR 2.7).
- Prospective feasibility across 30 centers supports bedside precision stratification.